DCPH
Deciphera Pharmaceuticals, Inc.
1 day chart
About DCPH
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. The Company has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a broad portfolio of medicines. The Company has one approved drug, QINLOCK, which is a switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition, the Company is developing three clinical-stage drug candidates, which includes Vimseltinib (DCC-3014) - colony stimulating factor 1 receptor (CSF1R) Kinase Inhibition for Tenosynovial Giant Cell Tumor (TGCT), Rebastinib - TEK tyrosine kinase (TIE2) Kinase Inhibition for advanced or Metastatic Solid Tumors, and DCC-3116 - ULK Kinase Inhibition for Mutant RAS/RAF Cancers.
Buy US stocks in Australia with $0 brokerage and trade DCPH today!
$1.22B
-
0.00%
783.66K
$19.17
$18.56
$18.56
$37.99
$6.51
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.